Log in

NASDAQ:KALV - Kalvista Pharmaceuticals Stock Price, Forecast & News

$16.86
+1.41 (+9.13 %)
(As of 12/13/2019 02:49 AM ET)
Today's Range
$15.40
Now: $16.86
$17.04
50-Day Range
$10.55
MA: $12.63
$16.88
52-Week Range
$9.86
Now: $16.86
$34.92
Volume197,138 shs
Average Volume144,156 shs
Market Capitalization$300.68 million
P/E RatioN/A
Dividend YieldN/A
Beta2.17
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, an intravitreally administered plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KALV
CUSIPN/A
Phone857-999-0075

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.13 million
Book Value$5.48 per share

Profitability

Net Income$-20,820,000.00
Net Margins-182.37%

Miscellaneous

Employees33
Market Cap$300.68 million
Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable

Receive KALV News and Ratings via Email

Sign-up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.


Kalvista Pharmaceuticals (NASDAQ:KALV) Frequently Asked Questions

What is Kalvista Pharmaceuticals' stock symbol?

Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

How were Kalvista Pharmaceuticals' earnings last quarter?

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) announced its earnings results on Tuesday, December, 3rd. The specialty pharmaceutical company reported ($0.33) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.55) by $0.22. The specialty pharmaceutical company earned $3.92 million during the quarter, compared to the consensus estimate of $3.23 million. Kalvista Pharmaceuticals had a negative net margin of 182.37% and a negative return on equity of 25.70%. View Kalvista Pharmaceuticals' Earnings History.

When is Kalvista Pharmaceuticals' next earnings date?

Kalvista Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Kalvista Pharmaceuticals.

What price target have analysts set for KALV?

5 brokers have issued 1-year target prices for Kalvista Pharmaceuticals' stock. Their forecasts range from $28.00 to $32.00. On average, they anticipate Kalvista Pharmaceuticals' stock price to reach $30.40 in the next year. This suggests a possible upside of 80.3% from the stock's current price. View Analyst Price Targets for Kalvista Pharmaceuticals.

What is the consensus analysts' recommendation for Kalvista Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kalvista Pharmaceuticals.

Has Kalvista Pharmaceuticals been receiving favorable news coverage?

News coverage about KALV stock has trended negative recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kalvista Pharmaceuticals earned a news impact score of -2.0 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Kalvista Pharmaceuticals.

Are investors shorting Kalvista Pharmaceuticals?

Kalvista Pharmaceuticals saw a increase in short interest in November. As of November 29th, there was short interest totalling 832,000 shares, an increase of 12.4% from the November 14th total of 740,400 shares. Based on an average trading volume of 153,000 shares, the days-to-cover ratio is currently 5.4 days. Currently, 6.6% of the shares of the stock are sold short. View Kalvista Pharmaceuticals' Current Options Chain.

Who are some of Kalvista Pharmaceuticals' key competitors?

What other stocks do shareholders of Kalvista Pharmaceuticals own?

Who are Kalvista Pharmaceuticals' key executives?

Kalvista Pharmaceuticals' management team includes the folowing people:
  • Mr. Thomas Andrew Crockett, CEO & Director (Age 44)
  • Mr. Benjamin L. Palleiko, Chief Bus. Officer & CFO (Age 53)
  • Mr. Andreas Maetzel M.D., M.Sc., Ph.D., Sr. VP of Medical (Age 56)
  • Mr. John B. McKune, VP of Fin. (Age 43)
  • Dr. Edward P. Feener, Chief Scientific Officer (Age 59)

Who are Kalvista Pharmaceuticals' major shareholders?

Kalvista Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Eventide Asset Management LLC (9.43%), Pictet Asset Management Ltd. (3.06%), State Street Corp (1.28%), Squarepoint Ops LLC (0.70%), Point72 Asset Management L.P. (0.49%) and Orbimed Advisors LLC (0.22%). Company insiders that own Kalvista Pharmaceuticals stock include Albert Cha, Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Daniel B Soland, Edward P Feener, Life Sciences Fund Iv (Gp) Sv, Svlsf Iv, Llc, Thomas Andrew Crockett and Venrock Healthcare Capital Par. View Institutional Ownership Trends for Kalvista Pharmaceuticals.

Which major investors are selling Kalvista Pharmaceuticals stock?

KALV stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Point72 Asset Management L.P. and Barclays PLC. Company insiders that have sold Kalvista Pharmaceuticals company stock in the last year include Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Edward P Feener, Life Sciences Fund Iv (Gp) Sv, Svlsf Iv, Llc, Thomas Andrew Crockett and Venrock Healthcare Capital Par. View Insider Buying and Selling for Kalvista Pharmaceuticals.

Which major investors are buying Kalvista Pharmaceuticals stock?

KALV stock was bought by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Pictet Asset Management Ltd., Squarepoint Ops LLC, Orbimed Advisors LLC, State Street Corp and Tower Research Capital LLC TRC. Company insiders that have bought Kalvista Pharmaceuticals stock in the last two years include Albert Cha and Daniel B Soland. View Insider Buying and Selling for Kalvista Pharmaceuticals.

How do I buy shares of Kalvista Pharmaceuticals?

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Kalvista Pharmaceuticals' stock price today?

One share of KALV stock can currently be purchased for approximately $16.86.

How big of a company is Kalvista Pharmaceuticals?

Kalvista Pharmaceuticals has a market capitalization of $300.68 million and generates $16.13 million in revenue each year. The specialty pharmaceutical company earns $-20,820,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe.View Additional Information About Kalvista Pharmaceuticals.

What is Kalvista Pharmaceuticals' official website?

The official website for Kalvista Pharmaceuticals is http://www.kalvista.com/.

How can I contact Kalvista Pharmaceuticals?

Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]


MarketBeat Community Rating for Kalvista Pharmaceuticals (NASDAQ KALV)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  244 (Vote Outperform)
Underperform Votes:  164 (Vote Underperform)
Total Votes:  408
MarketBeat's community ratings are surveys of what our community members think about Kalvista Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel